Researchers in the United States have created an experimental compound called SLU-PP-332 that tells skeletal muscle to behave as if the body were in constant endurance training. In mouse studies, twice-daily injections for one month cut body-fat gains more than ten-fold, produced a 12 % weight loss and let the animals run nearly 50 % farther without eating less or moving more.
The drug activates a family of “exercise genes” known as ERR receptors. These receptors normally switch on only during prolonged activity; once triggered by the molecule they boost fatty-acid burning and overall energy use, protecting lean muscle while removing excess fat.
Because SLU-PP-332 works on metabolism rather than on appetite, scientists think it could help people who cannot exercise enough, such as older adults, patients with heart failure, or those recovering from illness, avoid the usual muscle loss seen during fast weight-loss treatments. It might also slow metabolic diseases linked to obesity and age.
The results are still pre-clinical. The team must refine the molecule, turn injections into pills, and carry out safety tests in further animals before any human trials begin. For most people, regular physical activity remains essential because it benefits the heart, brain and mood in ways a single drug cannot yet match.
A Synthetic ERR Agonist Alleviates Metabolic Syndrome – Journal of Pharmacology and Experimental Therapeutics, 17 January 2024
Laboratory mice given SLU-PP-332 burned more fat, showed higher energy expenditure and improved insulin sensitivity without eating less. DOI: 10.1124/jpet.123.001733.
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity – ACS Chemical Biology, March 2023.
Shows the same compound lengthens treadmill running time by 70 % in normal-weight mice and maps the underlying gene program. DOI: 10.1021/acschembio.2c00720.
0 Comments